Australia markets closed

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.2800-0.0100 (-0.44%)
At close: 04:00PM EDT
2.2200 -0.06 (-2.63%)
After hours: 05:05PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
16,007
16,526
24,468
29,115
31,830
Selling general and administrative
7,079
6,881
8,097
9,515
11,930
Total operating expenses
23,086
23,407
32,565
38,630
43,760
Operating income or loss
-23,086
-23,407
-32,565
-38,630
-43,760
Interest expense
-
-
-
15
-
Total other income/expenses net
-3,295
-5,206
-9,396
-4,596
37,225
Income before tax
-24,857
-27,029
-41,307
-43,241
-5,995
Income from continuing operations
-24,857
-27,029
-41,307
-43,241
-5,995
Net income
-24,857
-27,029
-41,307
-43,241
-5,995
Net income available to common shareholders
-24,857
-27,029
-41,307
-43,241
-5,995
Basic EPS
-0.64
-
-0.89
-1.03
-0.20
Diluted EPS
-0.64
-
-0.89
-1.03
-0.20
Basic average shares
47,401
-
46,554
41,854
29,479
Diluted average shares
47,401
-
46,554
41,854
29,479